• P2Y2R-Driven Microglial Clearance of Aβ1–42

  2026-09-17

  Kim et al. showed that fibrillar and oligomeric Aβ1–42 stimulate extracellular nucleotide release from microglia, activating P2Y2 receptors on neighboring cells to promote migration, peptide uptake, and degradation. The study identifies a nucleotide-dependent microglial clearance circuit and provides experimentally useful parameters for investigating Aβ42 peptide handling in Alzheimer’s disease models.

• Temozolomide B1399: Reproducible Assay Workflows

  2026-09-16

  This scenario-driven guide explains how Temozolomide, SKU B1399, can improve experimental consistency in viability, cytotoxicity, DNA repair, and glioma studies. It covers mechanism, ATRX-informed design, DMSO formulation, data interpretation, and practical vendor-selection criteria.

• FPS-ZM1 and RAGE: From Metabolism to AD

  2026-09-16

  A translational analysis of how RAGE biology connects hypothalamic metabolic stress with amyloid beta signaling, and how FPS-ZM1 can help researchers test receptor-level causality in Alzheimer’s disease research.

• Multiple Myeloma Cell-Line Mutational Landscapes

  2026-09-15

  Vikova and colleagues used whole-exome sequencing across 30 human multiple myeloma cell lines and eight control samples to define recurrent protein-altering mutations, pathway disruptions, and genotype–drug-response associations. The study provides a practical framework for selecting molecularly appropriate models in multiple myeloma and hematological malignancy research while clarifying the limits of cell-line-based inference.

• FPS-ZM1: Designing Causal RAGE Studies

  2026-09-15

  FPS-ZM1 is a selective RAGE inhibitor for separating receptor engagement from downstream amyloid beta and neuroinflammatory effects. This article translates RAGE/POMC findings into a rigorous assay strategy without conflating berberine evidence with FPS-ZM1 activity.

• 4-Phenylbutyric Acid in ER Stress Assays

  2026-09-14

  Discover how 4-PBA can function as a mechanistic perturbation tool rather than a generic ER stress inhibitor. This guide uses PFOS-exposed kidney-cell research to show how chemical chaperone experiments can separate proteostasis failure from ferroptosis and other cell-death outcomes.

• PAD4-IN-2 TFA: A Causal Research Framework

  2026-09-14

  PAD4-IN-2 TFA, also known as Compound 5i TFA, is best studied as a spatially selective probe of the PAD4–H3cit–NET axis rather than as a conventional cytotoxic agent. This article presents a causal assay framework linking tumor uptake, neutrophil biology, metastasis, and immune remodeling.

• Arrb2, 6-ketoLCA, and Hepatic IRI

  2026-09-13

  The reference study identifies a hepatocyte-specific Arrb2–6-ketoLCA pathway that promotes M2 macrophage polarization and attenuates hepatic ischemia–reperfusion injury. By integrating clinical samples, a mouse ischemia–reperfusion model, hypoxia–reoxygenation experiments, and metabolite analysis, it provides a mechanistic framework for studying hepatocyte–macrophage communication in liver injury.

• Intestinal TM6SF2 and the Gut–Liver Axis in MASH

  2026-09-12

  This study shows that intestinal, rather than only hepatic, TM6SF2 deficiency can initiate MASH through barrier dysfunction, microbial dysbiosis, and gut-derived lysophosphatidic acid. Its combination of epithelial genetics, fecal transfer, co-housing, metabolite analysis, and receptor pharmacology provides a causal framework for studying the gut–liver axis and for evaluating downstream inflammatory interventions.

• Radiotherapy, PD-1/TIGIT Blockade, and CD8+ Memory

  2026-09-11

  The reference study shows that radiotherapy combined with PD-1 and TIGIT blockade produces local and abscopal tumor control while establishing durable CD8+ T-cell memory in several mouse models. Its integrated immune profiling identifies activated CD8+ T cells, M1-like macrophages, inflammatory chemokines, and sustained cytokine signaling as important components of the response.

• Amyloid Beta-Peptide (1-40): Assay Guide

  2026-09-11

  Build reproducible aggregation, membrane-interaction, and neurotoxicity workflows with a defined human Aβ40 sequence. This guide translates calcium-sensitive surface measurements into practical assay design, controls, and troubleshooting for Alzheimer’s disease research.

• Annexin V in Trophoblast–T Cell Apoptosis Assays

  2026-09-10

  Learn how Annexin V, a calcium-dependent phosphatidylserine binding protein, can add a membrane-state readout to trophoblast–T cell and exosome studies. This article translates recent preeclampsia findings into a rigorous apoptosis assay design and interpretation framework.

• Amyloid β-Peptide (1-42): Assay-State Strategy

  2026-09-10

  Explore how Amyloid β-Peptide (1-42) and its aggregation state shape neuronal toxicity, ion-channel responses, and assay interpretation. This guide translates evidence from SH-SY5Y models into a practical, state-aware workflow for Alzheimer’s disease research.

• Sunitinib Workflows for RCC and Angiogenesis

  2026-09-09

  Build reproducible Sunitinib assays for receptor signaling, renal cell carcinoma, apoptosis, cell-cycle analysis, and tumor angiogenesis. This guide combines practical dosing and formulation advice with a combination-testing framework inspired by recent research on overcoming Sunitinib resistance.

• FPS-ZM1: A RAGE Inhibitor Assay Workflow

  2026-09-09

  Build a receptor-focused workflow with FPS-ZM1 to separate RAGE-dependent amyloid beta signaling, neuronal stress, and neuroinflammation from broader metabolic effects. The guide translates emerging RAGE/POMC findings into practical controls, solvent handling, readouts, and troubleshooting decisions.

8059 records 1/538 page Next 12345 下5页 Last page